New drug aims to calm swollen eyes in thyroid disease patients

NCT ID NCT06557850

Ongoing Disease control Sponsor: H. Lundbeck A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called Lu AG22515 in 20 adults with moderate-to-severe thyroid eye disease, an autoimmune condition that causes eye swelling and bulging. The main goal is to see if the drug can reduce eye bulging over 24 weeks. Participants receive the drug and are monitored for safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID EYE DISEASE

Contacts and locations

Locations

Diagnostic-Consultative Center Alexandrovska

Sofia, 1431, Bulgaria
Jagiellonian University Medical College

Krakow, Lesser Poland Voivodeship, 30-688, Poland
Uniewrsyteckie Centru Kliniczne

Katowice, 40-514, Poland
UnivCentrum Zdrowia MDM EB GROUP Sp.zo.o

Warsaw, 00-189, Poland
University Clinical Center of The Republic Of Srpska

Banja Luka, Republika Srpska, 78000, Bosnia and Herzegovina
University Specialized Hospital for Active Treatment in Endocrinology (USHATE) "Acad. Ivan Penchev"

Sofia, 1431, Bulgaria

More trials for these conditions

Other studies related to the condition(s) this trial covers.